Trials / Completed
CompletedNCT00539526
Evaluation of Hyperemia With the Use of Ocular Prostaglandin Analogues
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 106 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate hyperemia and ocular surface tolerability in patients on prostaglandin analogues
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Bimatoprost 0.03% | bimatoprost 0.03%, 1 drop nightly for 3 months |
| DRUG | travoprost 0.004% | travoprost 0.004% eye drops, 1 drop nightly for 3 months |
| DRUG | latanoprost 0.005% eye drops | latanoprost 0.005%, 1 drop nightly for 3 months |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2008-07-01
- Completion
- 2008-09-01
- First posted
- 2007-10-04
- Last updated
- 2019-04-24
- Results posted
- 2011-10-31
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00539526. Inclusion in this directory is not an endorsement.